MANHATTAN PHARMACEUTICALS DOSES FIRST PATIENT GROUP IN PHASE IIA TRIAL FOR OE, ITS ORAL OBESITY DRUG CANDIDATE

Manhattan Pharmaceuticals, Inc. today announced that it commenced dosing the first group of patients in its Phase IIa clinical trial of oral Oleoyl-estrone (OE), the company's novel drug candidate for the treatment of obesity. Patient recruitment is ongoing. Yahoo News (http://biz.yahoo.com/prnews/060629/nyth096.html?.v=61)